As for cancer diseases, the CCR2-CCL2 is likely to be involved by two different mechanisms: directing the recruitment and accumulation of TAMS and monocytic myeloid-derived suppressor cells (monocytic MDSC) at the tumor site to support tumor growth and suppress the anti-tumor immune response, and direct effect on tumor growth. This evidence concerns the gene CCL2 and neoplasm.